Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.
García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R, On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin. García-Fortes M, et al. Among authors: angona a. Cancers (Basel). 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. Cancers (Basel). 2022. PMID: 35565461 Free PMC article.
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Hernández-Boluda JC, et al. Among authors: angona a. Br J Haematol. 2011 Jan;152(1):81-8. doi: 10.1111/j.1365-2141.2010.08430.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083657 Free article.
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C. Alvarez-Larrán A, et al. Among authors: angona a. Blood. 2012 Feb 9;119(6):1363-9. doi: 10.1182/blood-2011-10-387787. Epub 2011 Dec 12. Blood. 2012. PMID: 22160617 Free article.
Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F. Martínez-Trillos A, et al. Among authors: angona a. Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15. Ann Hematol. 2014. PMID: 24337516
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C. Alvarez-Larrán A, et al. Among authors: angona a. Am J Hematol. 2014 May;89(5):517-23. doi: 10.1002/ajh.23676. Epub 2014 Feb 21. Am J Hematol. 2014. PMID: 24458835 Free article.
WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.
Alvarez-Larrán A, Ancochea A, García M, Climent F, García-Pallarols F, Angona A, Senín A, Barranco C, Martínez-Avilés L, Serrano S, Bellosillo B, Besses C. Alvarez-Larrán A, et al. Among authors: angona a. Br J Haematol. 2014 Sep;166(6):911-9. doi: 10.1111/bjh.12990. Epub 2014 Jun 24. Br J Haematol. 2014. PMID: 24957246 Free article.
57 results